LEADER 02874nam 2200469 450 001 9910827837403321 005 20230808193238.0 010 $a0-309-38102-9 010 $a0-309-38100-2 035 $a(CKB)3710000000685049 035 $a(EBL)4528558 035 $a(MiAaPQ)EBC4528558 035 $a(EXLCZ)993710000000685049 100 $a20160616h20162016 uy| 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aGlobal health risk framework - research and development of medical products $eworkshop summary /$fTheresa Wizemann, Michelle A. Mancher, and Anne B. Claiborne, rapporteurs ; Board on Health Sciences Policy, Institute of Medicine ; The National Academies of Sciences, Engineering, Medicine 210 1$aWashington, District of Columbia :$cThe National Academies Press,$d[2016] 210 4$dİ2016 215 $a1 online resource (141 p.) 300 $aDescription based upon print version of record. 311 $a0-309-38099-5 327 $aPages:1 to 25; Pages:26 to 50; Pages:51 to 75; Pages:76 to 100; Pages:101 to 125; Pages:126 to 141 330 $a"Since the 2014 Ebola outbreak many public- and private-sector leaders have seen a need for improved management of global public health emergencies. The effects of the Ebola epidemic go well beyond the three hardest-hit countries and beyond the health sector. Education, child protection, commerce, transportation, and human rights have all suffered. The consequences and lethality of Ebola have increased interest in coordinated global response to infectious threats, many of which could disrupt global health and commerce far more than the recent outbreak. In order to explore the potential for improving international management and response to outbreaks the National Academy of Medicine agreed to manage an international, independent, evidence-based, authoritative, multistakeholder expert commission. As part of this effort, the Institute of Medicine convened four workshops in summer of 2015 to inform the commission report. The presentations and discussions from the Workshop on Research and Development of Medical Products are summarized in this report"--$cPublisher's description. 606 $aGlobalization$xHealth aspects$vCongresses 615 0$aGlobalization$xHealth aspects 676 $a614.4 702 $aWizemann$b Theresa M. 702 $aMancher$b Michelle A. 702 $aClaiborne$b Anne B. 712 02$aInstitute of Medicine.$bBoard on Health Sciences Policy, 712 02$aNational Academies of Sciences, Engineering, Medicine, 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910827837403321 996 $aGlobal health risk framework - research and development of medical products$94007370 997 $aUNINA